SavedAdd your journal

Journals / Interdisciplinary Medical Journal / 2026 / Volume: 17 Issue: 58

Assessment of the correlation between serum elafin concentrations and disease severity, erythrocyte sedimentation rate, and C-reactive protein levels in psoriasis patients

Yemliha Bozkurt0000-0001-9434-8355
Cigdem Dogramaci(MUSTAFA KEMAL ÜNİVERSİTESİ)0000-0003-4986-2149
Pages
—
Publication Date
2026-08-23
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Results: It was found that elafin levels were significantly higher in psoriasis patients than in the healthy control group (p=0.028).

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: This study was conducted to examine elafin levels between individuals with psoriasis and a healthy control group and to evaluate the relationship between elafin concentrations and disease severity, inflammatory markers, and lipid parameters.
📊
Key Findings & Data:Method: The study sample included 40 psoriasis individuals in the Hatay Mustafa Kemal University Hospital Dermatology outpatient clinic and 40 healthy individuals matching the patient group.
💡
Conclusion & Impact:Results: It was found that elafin levels were significantly higher in psoriasis patients than in the healthy control group (p=0.028).
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Psoriasis · elafin · C-reactive protein

Abstract

Objective: This study was conducted to examine elafin levels between individuals with psoriasis and a healthy control group and to evaluate the relationship between elafin concentrations and disease severity, inflammatory markers, and lipid parameters. Method: The study sample included 40 psoriasis individuals in the Hatay Mustafa Kemal University Hospital Dermatology outpatient clinic and 40 healthy individuals matching the patient group. All subjects were characterized using demographic information, physical measurements, and biochemical markers. Results: It was found that elafin levels were significantly higher in psoriasis patients than in the healthy control group (p=0.028). Low-density lipoprotein (LDL) and total cholesterol levels increased, whereas high-density lipoprotein (HDL) levels decreased. Elafin levels positively correlate with LDL and total cholesterol. Conclusion: Elafin levels were higher in psoriasis patients, but this phenomenon was unrelated to disease severity or inflammatory markers.The correlation between elafin and lipid markers indicates a possible association between elafin and metabolic changes in psoriasis.

🔖

Cite This Article

Bozkurt, Y., Dogramaci, C. (2026). Assessment of the correlation between serum elafin concentrations and disease severity, erythrocyte sedimentation rate, and C-reactive protein levels in psoriasis patients. Interdisciplinary Medical Journal, Volume: 17 Issue: 58. https://doi.org/10.17944/interdiscip.1882455

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (19)

  1. Kamiya K, Kishimoto M, Sugai J, Komine M, Ohtsuki M. Risk factors for the development of psoriasis. Int J Mol Sci. 2019;20(18):4347.
  2. Armstrong AW, Read C. Pathophysiology, clinical Presentation, and Treatment of Psoriasis: A Review. JAMA. 2020;323(19):1945-60. doi:10.1001/jama.2020.4006
  3. Boehncke WH, Boehncke S. More than skin-deep: The many dimensions of the psoriatic disease. Swiss Med Wkly. 2014:144:w13968. doi:10.4414/smw.2014.13968
  4. Rendon A, Schäkel K. Rendon, A., & Schäkel, K. Psoriasis Pathogenesis and Treatment. Int J Mol Sci. 2019;20(6):1475. doi:10.3390/ijms20061475. International Journal of Molecular Sciences. 2019.
  5. Grozdev I, Korman N, Tsankov N. Psoriasis as a systemic disease. Clin Dermatol. 2014;32(3):343-50. doi: 10.1016/j.clindermatol.2013.11.001
  6. Elgharib I, Khashaba SA, Elsaid HH, Sharaf MM. Serum elafin as a potential inflammatory marker in psoriasis. Int J Dermatol. 2019;58(2):205-9. doi:10.1111/ijd.14217
  7. Shaw L, Wiedow O. Therapeutic potential of human elafin. Biochem Soc Trans. 2011;39(5):1450-4. doi:10.1042/BST0391450
  8. Boehncke WH, Schön MP. Psoriasis. Lancet. 2015;386(9997):983-94. doi:10.1016/S0140-6736(14)61909-7
  9. Zeng J, Luo S, Huang Y, Lu Q. Critical role of environmental factors in the pathogenesis of psoriasis. J Dermatol. 2017;44(8):863-72 doi:10.1111/1346-8138.13806
  10. de Felice C, Marulli GC, Ardigò M, Berardesca E. Biological markers in the etiology of psoriasis: Targeted treatment options. Biologics. 2007;1(1):11-8.
  11. Truong B, Rich-Garg N, Ehst BD, Deodhar AA, Ku JH, Vakil-Gilani K, et al. Demographics, clinical disease characteristics, and quality of life in a large cohort of psoriasis patients with and without psoriatic arthritis. Clin Cosmet Investig Dermatol. 2015;8:563-9. doi:10.2147/CCID.S90270
  12. Strober BE, Bissonnette R, Fiorentino D, Kimball AB, Naldi L, Shear NH, et al. Comparative effectiveness of biologic agents for the treatment of psoriasis in a real-world setting: Results from a large, prospective, observational study (Psoriasis Longitudinal Assessment and Registry [PSOLAR]). J Am Acad Dermatol. 2016;74(5):851-61. doi:10.1016/j.jaad.2015.12.017
  13. Özkaya DB, Onsun N, Topukçu B, Su Ö, Dizman D, Uysal Ö. Türk toplumunda psoriasisli hastalarda vücut kitle indeksi ve psoriasis alan şiddet indeksi ilişkisi. Turkderm Deri Hastaliklari ve Frengi Arsivi. 2014;48(3):127-30. doi:10.4274/turkderm.47587
  14. Holmannova D, Borsky P, Borska L, Andrys C, Hamakova K, Rehacek V, et al. Metabolic syndrome, clusterin and elafin in patients with psoriasis vulgaris. Int J Mol Sci. 2020;21(16):5617. doi:10.3390/ijms21165617.
  15. Vadakayil A, Dandekeri S, Kambil S, Ali N. Role of C-reactive protein as a marker of disease severity and cardiovascular risk in patients with psoriasis. Indian Dermatol Online J. 2015;6(5):322-5. doi:10.4103/2229-5178.164483
  16. Giang J, Seelen MAJ, van Doorn MBA, Rissmann R, Prens EP, Damman J. Complement activation in inflammatory skin diseases. Front Immunol. 2018;9:639. doi:10.3389/fimmu.2018.00639
  17. Matwiejuk M, Kulczyńska-Przybik A, Myśliwiec H, Chabowski A, Mroczko B, Flisiak I. The Role of Selected Proteins in the Pathogenesis of Psoriasis. Int J Mol Sci. 2025;26(13):6475. doi:10.3390/ijms26136475
  18. Alghonemy SM, Obaid Z, Elbendary A, Fouda I. Assessment of serum elafin as a possible inflammatory marker in psoriasis. Al-Azhar Assiut Medical Journal. 2020;18(4):408-12. doi:10.4103/azmj.azmj_86_20
  19. Yi J, Xu M, Han L, Dong Z, Liu R, Zhang X, et al. A Multicenter Validation of a Fully Automated Chemiluminescence Immunoassay for Plasma Elafin in Psoriasis Diagnosis and Severity Assessment. Advanced Science. 2025;12(47):e11535 doi:10.1002/advs.202511535